JP2016513656A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513656A5
JP2016513656A5 JP2016502156A JP2016502156A JP2016513656A5 JP 2016513656 A5 JP2016513656 A5 JP 2016513656A5 JP 2016502156 A JP2016502156 A JP 2016502156A JP 2016502156 A JP2016502156 A JP 2016502156A JP 2016513656 A5 JP2016513656 A5 JP 2016513656A5
Authority
JP
Japan
Prior art keywords
substituted
heterocycle
alkyl
aryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502156A
Other languages
English (en)
Japanese (ja)
Other versions
JP6378308B2 (ja
JP2016513656A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/026498 external-priority patent/WO2014160401A1/en
Publication of JP2016513656A publication Critical patent/JP2016513656A/ja
Publication of JP2016513656A5 publication Critical patent/JP2016513656A5/ja
Application granted granted Critical
Publication of JP6378308B2 publication Critical patent/JP6378308B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502156A 2013-03-13 2014-03-13 がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての3−(アリールまたはヘテロアリール)メチレンインドリン−2−オン誘導体 Expired - Fee Related JP6378308B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361780248P 2013-03-13 2013-03-13
US201361780263P 2013-03-13 2013-03-13
US61/780,263 2013-03-13
US61/780,248 2013-03-13
PCT/US2014/026498 WO2014160401A1 (en) 2013-03-13 2014-03-13 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018129002A Division JP2018168187A (ja) 2013-03-13 2018-07-06 がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての3−(アリールまたはヘテロアリール)メチレンインドリン−2−オン誘導体

Publications (3)

Publication Number Publication Date
JP2016513656A JP2016513656A (ja) 2016-05-16
JP2016513656A5 true JP2016513656A5 (enExample) 2017-04-20
JP6378308B2 JP6378308B2 (ja) 2018-08-22

Family

ID=50639949

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016502156A Expired - Fee Related JP6378308B2 (ja) 2013-03-13 2014-03-13 がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての3−(アリールまたはヘテロアリール)メチレンインドリン−2−オン誘導体
JP2018129002A Pending JP2018168187A (ja) 2013-03-13 2018-07-06 がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての3−(アリールまたはヘテロアリール)メチレンインドリン−2−オン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018129002A Pending JP2018168187A (ja) 2013-03-13 2018-07-06 がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての3−(アリールまたはヘテロアリール)メチレンインドリン−2−オン誘導体

Country Status (14)

Country Link
US (2) US20160031888A1 (enExample)
EP (1) EP2970206A1 (enExample)
JP (2) JP6378308B2 (enExample)
KR (1) KR20150127249A (enExample)
CN (1) CN105408320B (enExample)
AU (2) AU2014243869A1 (enExample)
BR (1) BR112015022431A2 (enExample)
CA (1) CA2904152A1 (enExample)
HK (1) HK1220184A1 (enExample)
IL (1) IL240960A0 (enExample)
MX (1) MX2015011456A (enExample)
RU (2) RU2019104092A (enExample)
SG (2) SG11201507346PA (enExample)
WO (1) WO2014160401A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104876928B (zh) * 2015-05-07 2016-09-14 浙江司太立制药股份有限公司 7-氮杂吲哚啉-2-酮类化合物及其制备方法
JPWO2017026119A1 (ja) * 2015-08-10 2018-05-24 大日本住友製薬株式会社 5−(チアゾール−4−イル)インドリン−2−オン誘導体の精製方法
EA201891136A1 (ru) * 2015-11-12 2018-10-31 ЭлДжи КЕМ, ЛТД. Фармацевтическая композиция, содержащая в качестве активного ингредиента производное 7-азаиндолин-2-она или его фармацевтически приемлемую соль
CN105461705B (zh) * 2015-11-30 2018-04-10 中国医科大学 二苯并氮杂卓二酮类抗肿瘤化合物及其制备方法
WO2018005444A2 (en) 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
CN107698593A (zh) * 2016-08-09 2018-02-16 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
CN106432228A (zh) * 2016-09-06 2017-02-22 浙江司太立制药股份有限公司 含有4‑肟基‑1‑哌啶基片段的7‑氮杂吲哚啉‑2‑酮类化合物及其制备方法
CN106397436A (zh) * 2016-09-06 2017-02-15 浙江司太立制药股份有限公司 5‑溴‑7‑氮杂吲哚啉‑2‑酮类化合物及其制备方法
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
WO2019002889A1 (en) 2017-06-30 2019-01-03 Industrial Technology Research Institute METHOD FOR TREATING AUTOIMMUNE NEUROLOGICAL DISEASE AND / OR NEURODEGENERATIVE DISEASE AND PHARMACEUTICAL FORMULAS FOR LIQUID GALENIC FORM AND CONTROLLED RELEASE GALENIC FORM
CN110357878B (zh) * 2018-03-26 2022-04-12 武汉誉祥医药科技有限公司 1,3-二氢-2H-吡咯并[3,2-b]吡啶-2-酮衍生物及其医药用途
UA127357C2 (uk) 2018-04-18 2023-07-26 Констеллатіон Фармацеутікалс, Інк. Модулятори метилмодифікуючих ферментів, композиції та їх використання
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US12318381B2 (en) * 2018-09-18 2025-06-03 1Globe Biomedical Co., Ltd. Treatment for non-alcoholic fatty liver disease
JP7589949B2 (ja) * 2018-09-18 2024-11-26 1グローブ バイオメディカル カンパニー, リミテッド 肥満に対する処置
WO2021003339A1 (en) * 2019-07-03 2021-01-07 The Regents Of The University Of Colorado, A Body Corporate Amp-activated protein kinase inhibitors and methods of making and using the same
MD4003532T2 (ro) 2019-07-24 2025-01-31 Constellation Pharmaceuticals Inc Forme cristaline de 7-clor-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-N-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamidă
US20230212120A1 (en) * 2020-05-29 2023-07-06 The Regents Of The University Of Michigan Small molecule inhibitors of grk5 and grk5 subfamily members and uses thereof
CN111675647B (zh) * 2020-06-26 2022-03-01 深圳技术大学 2-吲哚酮类pak1抑制剂及其在抗肿瘤治疗药物中的应用
KR20230037564A (ko) * 2020-07-10 2023-03-16 블로썸힐 테라퓨틱스, 인크. 거대고리 화합물 및 그의 용도
CA3246487A1 (en) * 2022-01-05 2023-07-13 Blossomhill Therapeutics, Inc. MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
CN114213396B (zh) * 2022-01-27 2023-03-24 深圳市乐土生物医药有限公司 一种吲哚-2-酮类化合物及其制备方法与用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (enExample) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
WO1997013767A1 (de) * 1995-10-09 1997-04-17 Chemisch Pharmazeutische Forschungsgesellschaft Mbh Heterocyclisch substituierte 1-indolcarboxamide als cyclooxygenase-2 inhibitoren
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
BR9916223A (pt) * 1998-12-17 2001-09-04 Hoffmann La Roche 4-ariloxindóis como inibidores de cinases de proteìna jnk
AU2728201A (en) * 1999-12-21 2001-07-03 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
DE122008000002I1 (de) * 2000-02-15 2008-04-17 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
US6635640B2 (en) * 2000-06-30 2003-10-21 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
WO2002055517A2 (en) * 2000-12-20 2002-07-18 Jingrong Cui 4-(hetero)aryl substituted indolinones
AR038957A1 (es) * 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
AU2004284084A1 (en) * 2003-10-24 2005-05-06 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
EP1828123A1 (en) * 2004-12-17 2007-09-05 Boehringer Ingelheim International GmbH Indolinones and their use as antiproliferative agents
US20070032555A1 (en) 2005-07-01 2007-02-08 Concert Pharmaceuticals Inc. Novel aryloxyphenyl-propanamines
US20070116643A1 (en) 2005-07-01 2007-05-24 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
WO2007016431A2 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel benzo [d] [1,3]-dioxol derivatives
WO2007016361A2 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
EP1981884B1 (en) * 2006-01-18 2012-06-13 Amgen, Inc Thiazole compounds as protein kinase b (pkb) inhibitors
CN101007801A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯取代的2-二氢吲哚酮衍生物、其制法与医药上的用途
WO2008045627A2 (en) * 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof
CN101848908B (zh) * 2007-09-06 2014-07-02 北京强新生物科技有限公司 激酶抑制剂的组合物及其在治疗癌症和其它与激酶相关的疾病中的用途
EA019507B1 (ru) * 2008-05-13 2014-04-30 Айрм Ллк Конденсированные азотсодержащие гетероциклы и содержащие их композиции в качестве ингибиторов киназы
US8853420B2 (en) * 2008-07-29 2014-10-07 Boehringer Ingelheim International Gmbh Compounds
US9187454B2 (en) * 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
US9227962B2 (en) * 2013-03-13 2016-01-05 Boston Biomedical, Inc. Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative
US9795595B2 (en) * 2014-01-27 2017-10-24 Boston Biomedical, Inc. Methods for treating cancer

Similar Documents

Publication Publication Date Title
JP6378308B2 (ja) がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての3−(アリールまたはヘテロアリール)メチレンインドリン−2−オン誘導体
JP2016513656A5 (enExample)
CA2633023C (en) Polycyclic indazole derivatives that are erk inhibitors
CN114269735A (zh) 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
EP4351558A1 (en) Compounds having 5-(2-fluoro-6-hydroxyphenyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide as inhibitors of protein kinase phosphatase enzymes
JP6305510B2 (ja) ヤヌスキナーゼ阻害剤としての非環式シアノエチルピラゾロピリドン
CN101848908A (zh) 激酶抑制剂的组合物及其在治疗癌症和其它与激酶相关的疾病中的用途
US20190241550A1 (en) Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative
AU2014234907B2 (en) Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors
CN110156656B (zh) 五元杂芳环衍生物、其制备方法、药物组合物及应用
AU2021410926A1 (en) Tetrahydrothienopyrimidinesulfonamide compounds
CA3167785A1 (en) Heterocyclic compounds for modulating nr2f6
EP4602043A1 (en) 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
JP2024508769A (ja) Wee-1阻害剤としてのピリミジン化合物
CN113880833A (zh) 联苯多环类衍生物抑制剂、其制备方法和应用
RU2802283C2 (ru) Новый ингибитор на основе производного хинолина
CN120858099A (zh) Cdk抑制剂
HK1187606B (en) Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
HK1187606A1 (zh) 取代的6,6-稠合含氮杂环化合物及其用途
HK1139663A (en) Thiazoles and pyrazoles useful as kinase inhibitors
HK1122558A (en) Benzimidazoles useful as inhibitors of protein kinases
HK1148529B (en) Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases